CN101322702B - 哌拉西林钠舒巴坦钠药物组合物制剂 - Google Patents
哌拉西林钠舒巴坦钠药物组合物制剂 Download PDFInfo
- Publication number
- CN101322702B CN101322702B CN2008101348261A CN200810134826A CN101322702B CN 101322702 B CN101322702 B CN 101322702B CN 2008101348261 A CN2008101348261 A CN 2008101348261A CN 200810134826 A CN200810134826 A CN 200810134826A CN 101322702 B CN101322702 B CN 101322702B
- Authority
- CN
- China
- Prior art keywords
- high speed
- injection
- purification
- adverse current
- sulbactam sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229960000614 sulbactam sodium Drugs 0.000 title claims abstract description 56
- NKZMPZCWBSWAOX-IBTYICNHSA-M Sulbactam sodium Chemical compound [Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)N2C(=O)C[C@H]21 NKZMPZCWBSWAOX-IBTYICNHSA-M 0.000 title claims abstract description 49
- 238000002347 injection Methods 0.000 title claims abstract description 40
- 239000007924 injection Substances 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 title claims abstract description 21
- 229960005264 piperacillin sodium Drugs 0.000 title claims abstract description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 96
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 72
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 63
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 23
- 239000000843 powder Substances 0.000 claims abstract description 21
- 239000002904 solvent Substances 0.000 claims abstract description 19
- 238000000746 purification Methods 0.000 claims description 39
- 230000002411 adverse Effects 0.000 claims description 35
- 239000000243 solution Substances 0.000 claims description 20
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 18
- 239000002994 raw material Substances 0.000 claims description 18
- 238000004108 freeze drying Methods 0.000 claims description 10
- 238000000926 separation method Methods 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000004090 dissolution Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 3
- 239000012982 microporous membrane Substances 0.000 claims description 2
- 238000010262 high-speed countercurrent chromatography Methods 0.000 abstract description 3
- 229960001701 chloroform Drugs 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000011017 operating method Methods 0.000 description 4
- 229960002292 piperacillin Drugs 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 229960005256 sulbactam Drugs 0.000 description 4
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 4
- 108090000204 Dipeptidase 1 Proteins 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- 102000006635 beta-lactamase Human genes 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 150000002960 penicillins Chemical class 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012372 quality testing Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588656 Neisseriaceae Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000028346 Pseudomonas aeruginosa infectious disease Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000004810 partition chromatography Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
样品 | 性状 | 酸度 | 澄明度 | 有关物质 (%) | 含量(%) |
实施例1 | 白色粉末 | 5.9 | 符合规定 | 1.24 | 100.7 |
实施例2 | 白色粉末 | 6.1 | 符合规定 | 1.39 | 99.9 |
实施例3 | 白色粉末 | 5.8 | 符合规定 | 4.32 | 100.1 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101348261A CN101322702B (zh) | 2008-08-01 | 2008-08-01 | 哌拉西林钠舒巴坦钠药物组合物制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101348261A CN101322702B (zh) | 2008-08-01 | 2008-08-01 | 哌拉西林钠舒巴坦钠药物组合物制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101322702A CN101322702A (zh) | 2008-12-17 |
CN101322702B true CN101322702B (zh) | 2010-08-18 |
Family
ID=40186505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008101348261A Expired - Fee Related CN101322702B (zh) | 2008-08-01 | 2008-08-01 | 哌拉西林钠舒巴坦钠药物组合物制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101322702B (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101632671B (zh) * | 2009-08-18 | 2010-12-29 | 海南永田药物研究院有限公司 | 一种哌拉西林钠舒巴坦钠药物组合物混悬粉针剂及其新应用 |
CN101696211B (zh) * | 2009-08-28 | 2012-06-27 | 海南美大制药有限公司 | 一种高纯度的舒巴坦钠化合物 |
CN101890015B (zh) * | 2010-07-29 | 2012-02-22 | 郝志艳 | 一种哌拉西林钠他唑巴坦钠药物组合物脂质体注射剂 |
CN101890014B (zh) * | 2010-07-29 | 2012-05-23 | 胡建荣 | 一种哌拉西林钠舒巴坦钠药物组合物脂质体注射剂 |
CN101983629B (zh) * | 2010-08-06 | 2012-01-11 | 胡建荣 | 一种哌拉西林钠舒巴坦钠药物组合物微球注射剂 |
JP6035420B2 (ja) * | 2012-09-14 | 2016-11-30 | ベイジン シンティエンユー テクノロジー ディベロップメント シーオー エルティーディー | ピペラシリンナトリウムとスルバクタムナトリウムの共晶及びその製造方法、並びに当該共晶を含む医薬組成物及びその応用 |
CN102898438B (zh) * | 2012-09-14 | 2014-12-24 | 北京新天宇科技开发有限公司 | 哌拉西林钠与舒巴坦钠共晶及其制备方法、以及包含该共晶的药物组合物及其应用 |
CN103301131A (zh) * | 2013-06-17 | 2013-09-18 | 四川制药制剂有限公司 | 注射用哌拉西林钠舒巴坦钠制备方法 |
CN105640958B (zh) * | 2016-01-04 | 2017-03-15 | 四川制药制剂有限公司 | 一种哌拉西林钠与舒巴坦钠的药物组合物 |
CN105476994A (zh) * | 2016-01-23 | 2016-04-13 | 邓爱相 | 哌拉西林钠和舒巴坦钠药物组合物 |
CN110123636B (zh) * | 2019-05-29 | 2021-11-09 | 广西壮族自治区中国科学院广西植物研究所 | 一种利用高速逆流色谱精制注射液的方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1167618A (zh) * | 1997-06-11 | 1997-12-17 | 广州威尔曼药业有限公司 | 抗β-内酰胺酶抗菌素复合物 |
-
2008
- 2008-08-01 CN CN2008101348261A patent/CN101322702B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1167618A (zh) * | 1997-06-11 | 1997-12-17 | 广州威尔曼药业有限公司 | 抗β-内酰胺酶抗菌素复合物 |
Also Published As
Publication number | Publication date |
---|---|
CN101322702A (zh) | 2008-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101322702B (zh) | 哌拉西林钠舒巴坦钠药物组合物制剂 | |
CN101322701B (zh) | 阿莫西林钠舒巴坦钠药物组合物制剂 | |
CN104800221B (zh) | 一种治疗敏感菌感染性疾病的药物盐酸头孢他美酯组合物 | |
EP2208732B1 (en) | Deshydroxy vancomycin, the preparation, pharmaceutical composition and the use | |
CN101279979B (zh) | 头孢孟多酯钠的分离纯化方法及冻干粉针制剂的制备方法 | |
JP7037495B2 (ja) | ポロキサマーを精製するための方法 | |
CN103536540B (zh) | 利福平冻干粉针及其制备方法 | |
CN109082445B (zh) | 一株银杏内生真菌的代谢产物产品及其在抗菌中的应用 | |
CN109053720B (zh) | 生物碱类化合物及其制备方法和用途 | |
CN101322685B (zh) | 注射用美洛西林钠舒巴坦钠及其冻干粉针剂的制备方法 | |
CN108250270A (zh) | 一种从发酵液中富集提取达托霉素的方法 | |
CN101348494A (zh) | 高纯度盐酸头孢甲肟及其制备方法 | |
Hunter et al. | Actinomycete metabolism: origin of the guanidine groups in streptomycin | |
CN104958318A (zh) | 一种治疗感染性疾病的药物舒巴坦钠组合物 | |
CN104095809A (zh) | 克林霉素磷酸酯注射液药物组合物和制法 | |
CN101279978B (zh) | 头孢硫脒的分离纯化方法及头孢硫脒粉针剂的制备方法 | |
CN108203723B (zh) | 一种发酵生产高含量多黏菌素b1的方法 | |
CN103113390B (zh) | 一种舒巴坦钠化合物及其与美洛西林钠的药物组合物 | |
CN101279980B (zh) | 头孢米诺钠的分离纯化方法及头孢米诺钠冻干粉针剂的制备方法 | |
CN113563426B (zh) | 奥利万星母核a82846b的分离纯化方法 | |
CN110117310B (zh) | 一种达托霉素的纯化方法 | |
CN101264054A (zh) | 利福霉素钠注射液及其制备方法 | |
CN110655557A (zh) | 一种纽莫康定b0丝氨酸类似物的分离纯化方法 | |
CN106589075B (zh) | 一种替考拉宁的提纯方法 | |
CN101265264B (zh) | 一种高纯度美洛西林钠及其粉针生产方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Hainan general Kang Li pharmaceutical Co. Ltd Assignor: Hainan Baina Pharmaceutical Development Co., Ltd. Contract record no.: 2012460000008 Denomination of invention: Piperacillin sodium and sulbactam sodium for injection and preparation of freeze-dried injection thereof Granted publication date: 20100818 License type: Exclusive License Open date: 20081217 Record date: 20120618 |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Hainan Baina Pharmaceutical Development Co., Ltd. Document name: Notification to Pay the Fees |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Hainan Baina Pharmaceutical Development Co., Ltd. Document name: Notification of Termination of Patent Right |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100818 Termination date: 20170801 |